Literature DB >> 9402164

Anthracyclines-paclitaxel combinations in the treatment of breast cancer.

P F Conte1, A Gennari.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402164     DOI: 10.1023/a:1008208002779

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Authors:  D Rischin; L K Webster; M J Millward; G C Toner; S Nawaratne; V Ganju; P Francis; J F Bishop
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling.

Authors:  Xun Zhu; Zhenjian He; Jueheng Wu; Jie Yuan; Weitao Wen; Yiwen Hu; Yi Jiang; Cuiji Lin; Qianhui Zhang; Min Lin; Henan Zhang; Wan Yang; Hong Chen; Lili Zhong; Zhigang She; Shengping Chen; Yongcheng Lin; Mengfeng Li
Journal:  Mar Drugs       Date:  2012-03-23       Impact factor: 6.085

3.  A phase II trial of paclitaxel and epirubicin in advanced breast cancer.

Authors:  D Rischin; J Smith; M Millward; C Lewis; M Boyer; G Richardson; G Toner; H Gurney; J McKendrick
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 4.  Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.

Authors:  Andreu Porta-Sánchez; Cameron Gilbert; Danna Spears; Eitan Amir; Joyce Chan; Kumaraswamy Nanthakumar; Paaladinesh Thavendiranathan
Journal:  J Am Heart Assoc       Date:  2017-12-07       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.